Introduction
============

McCune--Albright syndrome (MAS) is a rare congenital sporadic disorder arising from somatic activating mutations in the *GNAS* gene. The precise prevalence of MAS is unknown and is estimated to range between 1/100,000 and 1/1,000,000 ([@bib1], [@bib2]). MAS is defined historically as the triad of peripheral precocious puberty (PP), café-au-lait skin pigmentation and fibrous dysplasia (FD) of the bone ([@bib3]). Other associated hyperfunctioning endocrinopathies include hyperthyroidism, growth hormone excess, phosphate wasting and neonatal hypercortisolism ([@bib4]). PP is subclassified into peripheral PP (PPP) and central PP (CPP). PPP, which is also known as gonadotropin-releasing hormone (GnRH)-independent PP, is defined as early pubertal maturation that is not a result of central activation of the hypothalamic--pituitary--gonadal axis. CPP, which is GnRH-dependent PP, is based on hypothalamic--pituitary--gonadal axis activation associated with progressive pubertal development, accelerated growth rate and advancement of skeletal age. Symptoms of PP or FD are the most common reasons that patients seek medical support. PP is present in approximately 85% of female patients with MAS and is often the presenting feature ([@bib5]). Autonomous activation of ovarian tissue leads to intermittent development of ovarian cysts, resulting in vaginal bleeding upon resolution and subsequent oestrogen withdrawal ([@bib6], [@bib7]). Girls typically develop progressive PP marked by recurrent vaginal bleeding, increased breast development, accelerated growth velocity and bone age advancement with the potential complication of a significantly shorter adult height ([@bib6]).

To date, establishing a safe, effective and long-term treatment for PP in girls with MAS has been challenging, and the benefits of current interventions have not been well-established due to the rarity of patients and the heterogeneous nature of the disease. Aromatase inhibitors, which were originally developed for the treatment of oestrogen receptor-positive breast cancer, are relatively newer agents that have been used for the treatment of PP in girls with MAS. The first-generation aromatase inhibitor testolactone was found to have minimal success in the treatment of girls with MAS. One study of seven girls with MAS treated for at least 3 years showed a reduction in both serum oestradiol levels and the frequency of vaginal bleeding. However, the mean predicted adult height (PAH) was not significantly improved after treatment ([@bib8]). A second-generation aromatase inhibitor, fadrozole, has also been found to have no significant benefit in the treatment of PP in girls with MAS. One study followed 16 girls with MAS treated with fadrozole and found that it does not sufficiently block oestrogen synthesis in most girls with MAS-associated PPP and may impair the adrenocortical stress response ([@bib9]). A 36-month trial of the third-generation aromatase inhibitor letrozole in ten girls with MAS-associated PP found a significant decrease in the growth velocity standard deviation score and bone age-to-chronological age (BA/CA) ratio as well as cessation or slowing in their rates of bleeding over 12--36 months of therapy ([@bib10]); however, one girl experienced a ruptured ovarian cyst after 2 years of treatment. To that end, the objective of our study was to evaluate the safety and efficacy of letrozole in girls with progressive PP associated with MAS.

Materials and methods
=====================

This was a single-centre, retrospective analysis of subjects treated at Peking Union Medical College Hospital as part of a long-standing MAS natural history study. The study was approved by the Institutional Review Board of Peking Union Medical College Hospital (Number S-K445). Informed consent was obtained in accordance with the institutional guidelines.

Clinical documents, laboratory data and radiology studies from ten MAS patients treated with letrozole at Peking Union Medical College Hospital between September 1999 and December 2017 were retrospectively reviewed and those with PP were followed. Pre-treatment and on-treatment safety and efficacy measures were evaluated using paired *t*-tests, Wilcoxon matched-pairs and Wilcoxon signed-rank tests. The data were analysed using the R software (R i386 3.4.3.lnk, Bell Laboratory, NJ, USA), and figures were prepared using GraphPad Prism 7 (GraphPad Software). *P* values \<0.05 were considered statistically significant. Data are presented as means ± standard deviations and medians as appropriate depending on the normality of distribution.

Height and skeletal maturation
------------------------------

Height measurements were performed using a stadiometer and determined as the average of three serial morning values. Bone ages were determined using the Greulich and Pyle method ([@bib11]); the bone age obtained just prior to letrozole initiation was used as the baseline. When available, bone age and height measurements were used to determine pre-treatment and post-treatment skeletal maturation rates and growth velocities. Height and growth velocity were measured from normative reference data ([@bib12]).

Pelvic ultrasonography
----------------------

Transabdominal pelvic ultrasonography was performed at each evaluation at Peking Union Medical College Hospital. The pelvic ultrasonography finding obtained just prior to letrozole initiation was used as the baseline. Subjects who completed treatment as well as those remaining on treatment underwent pelvic ultrasonography, whereupon uterine volumes were calculated according to the formula: volume = length × width × thickness × 0.52 ([@bib13]).

Results
=======

Clinical characteristics at baseline
------------------------------------

The ten children included in our study received letrozole treatment for a minimum of 6 months. A diagnosis of MAS was made when at least two of the following cardinal features, based on previously published criteria ([@bib5]), were present: café-au-lait skin pigmentation, polyostotic/monostotic bone FD and hyperfunctioning endocrinopathies.

The baseline individual clinical characteristics of the ten subjects are summarised in [Table 1](#tbl1){ref-type="table"}. The mean age at initial signs of PP was 3.6 ± 1.9 years, while the mean age at diagnosis of MAS symptoms was 3.8 ± 1.9 years. Eight patients presented with FD; all eight had FD in the limbs and seven also had the condition in craniofacial bones (patients 1, 2, 3, 4, 6, 9 and 10). One patient developed anosmia (subject 10), one had bilateral neural tube stenosis (subject 1) and two had involvement of the axial skeleton (subjects 6 and 8). FD in the extremities usually presented with a pathological fracture (subject 9), three had hip bone involvement (subjects 1, 2, and 4) and one experienced limping (subject 2). Six patients had skin dysplasia. Subject 4 experienced visual deficit, and subject 1 developed growth hormone hypersecretion. Subjects 2, 6, 9, and 10 (i.e., 40% of patients) showed functional and/or morphological thyroid abnormalities, and subjects 9 and 10 (i.e., 20%) had clinical hyperthyroidism. Table 1Clinical characteristics of the ten patients with McCune--Albright syndrome complicated by PP.SubjectAge at diagnosis of MAS (years)Age at diagnosis of PP (years)Age at letrozole start (years)Treatment durationBA/CATanner stage (B/PH)Letrozole dose (mg/day)Growth *Z*-scoreGrowth velocity *Z*-scoreFDSDHearing or olfactory deficitsVDOther endocrino-pathies14.34.38.60.51.2III/II2.53.60.56(+)(−)(−)(−)GHH22.92.92.94.7(−)III/I1.3QD→1.3QOD1.1−0.37(+)(+)(−)(−)(−)35.556.30.71.17I/I2.50.50(+)(−)(−)(−)(−)442.74.15.21.86III/I2.510.83(+)(+)(−)Unilateral(−)53.93.93.93.21.7II/I2.52.6(−)(+)(−)(−)(−)(−)64.34.34.36.91.25IV/I2.51.60.17(−)(+)(−)(−)(−)710.62.31.24.14II--III/III1.3→2.53.61(−)(+)(−)(−)PH86.86.86.81.11.08III/I2.50.10.3(+)(−)(−)(−)(−)94.74.74.73.81.7II/I1.3→2.51.61.12(+)(+)(−)(−)HT100.60.66.175.921.4(−)1.9→2.51.80.08(+)(+)Anosmia(−)HT[^1]

Subjects 1 and 3 had received previous treatment for PP prior to starting letrozole; the former had experienced elevated levels of oestradiol (E~2~) while the latter had continuous vaginal bleeding ([Table 1](#tbl1){ref-type="table"}). These therapies were discontinued at or shortly after letrozole initiation. Tamoxifen was administered to patient 1 as an adjuvant therapy owing to unabated vaginal bleeding after initiating letrozole. Four girls were receiving a GnRH analogue, as they subsequently developed CPP from PPP.

Letrozole initiation and treatment duration
-------------------------------------------

The mean age at letrozole initiation was 4.5 ± 2.6 years. The letrozole dose differed between subjects. Six patients from the initial letrozole pilot study were dosed according to the parameters of that study (a single 2.5 mg dose once daily), three subjects shifted to a single 2.5 mg dose once daily from 1.25 mg or 1.88 mg dose once daily with pubertal progression and one subject reduced dosing from a single daily 1.25 mg dose every day to the same dose every other day after experiencing pubertal remission ([Table 1](#tbl1){ref-type="table"}). The mean duration of treatment was 3.3 ± 2.4 years.

Growth change
-------------

The subjects' mean BA/CA ratio, growth *Z*-score and growth velocity *Z*-score were significantly decreased after treatment. Data on bone ages pre-treatment, at baseline (start of letrozole therapy) and during treatment were available for six subjects; the values were used to determine the pre- and on-treatment BA/CA ratio. There was a significant decrease in the BA/CA ratio from a pre-treatment mean value of 1.93 ± 1.12 to an on-treatment mean value of 1.51 ± 1.23 (*P* = 0.016) after initiating letrozole ([Fig. 1A](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Pre-treatment and on-treatment growth *Z*-scores as well as growth velocity *Z*-scores were available for all ten subjects; the growth *Z*-score decreased significantly from a pre-treatment mean of 1.69 ± 1.1 to an on-treatment mean of 1.04 ± 1.1 (*P* = 0.02) ([Fig. 1B](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). There was a significant decrease in the growth velocity *Z*-score following letrozole treatment, from a pre-treatment mean of 0.41 ± 0.5 to −0.2 ± 0.31 on treatment ([Fig. 1C](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}, *P* \< 0.001).Figure 1Letrozole effects on bone age-to-chronological age (BA/CA) ratio, growth *Z*-score and growth velocity *Z*-score. There was a significant decrease in the BA/CA ratio (panel A, \**P* = 0.016), growth *Z*-score (panel B, \**P* = 0.02) and growth velocity *Z*-scores (panel C, \*\*\**P* \< 0.001) over the course of the treatment. Table 2Response to letrozole therapy in ten girls with precocious puberty and polyostotic fibrous dysplasia of the bone due to McCune--Albright syndrome.SubjectBA/CA (pre)BA/CA (on)Uterine volumes (pre)Uterine volumes (on)Growth *Z*-score (pre)Growth *Z*-score (on)Growth velocity *Z*-score (pre)Growth velocity *Z*-score (on)PAH (cm) *Z*-score (pre)PAH (cm) *Z*-score (on)11.21.099.610154 (3.6)157 (1.7)0.560.05177.3 (3.2)182.6 (4.2)2Null17.31.197.5 (1.1)124 (0.4)−0.37−0.33NullNull31.17Null7.5Null119 (0.5)123 (0.3)0−0.54NullNull41.860.842.93.3106 (1)134.7 (0)0.83−0.08131.8 (−5.4)170.4 (1.8)51.71.16.72.7113 (2.6)136.5 (2.7)Null0.05151.6 (−1.7)170.9 (1.9)61.25113.511.6137 (1.6)150 (−0.1)0.17−0.4159 (−0.3)162.6 (0.4)74.1447.610.7101 (3)113 (3.7)10.13NullNull81.08Null11.2Null120 (0.1)127 (0.1)0.3−0.27NullNull91.7Null4.33.6116 (1.6)139.5 (1.4)1.120.1NullNull101.416.316.6125.6 (1.8)147 (0.1)0.080.42156.7 (−0.7)162.6 (0.4)[^2]

PAH
---

PAH *Z*-scores were determined for four subjects, concluding the subject 1 for the complication of GHH, pre- and on-treatment according to previously described methods ([@bib14]). There was a significant increase over the letrozole treatment period from −2.03 ± 2.33 at baseline to 1.13 ± 0.84 on-treatment (*P* = 0.029) ([Fig. 2](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}).Figure 2Predicted adult height (PAH) *Z*-scores before and after letrozole treatment. There was a significant increase in the PAH *Z*-score over the treatment period. \**P* = 0.029.

Uterine volumes
---------------

Pre- and on-treatment pelvic ultrasonography data were available for eight subjects. There was no change in median uterine volumes over the letrozole treatment period (7.3 ± 3.2 cm^3^ to 7.5 ± 5.5 cm^3^ (*P* = 0.56) ([Table 2](#tbl2){ref-type="table"})). Since only the lengths and widths of the ovaries could be obtained, the ovarian volumes could not be calculated accurately.

Hormone levels
--------------

Pre- and on-treatment oestradiol levels were available for all the subjects. Given the episodic nature of oestradiol production in MAS, pre-treatment values varied in range from 2.5 pg/mL to 700 pg/mL (median, 182 ± 264 pg/mL). These levels were reduced following the initiation of letrozole treatment and ranged between 2.5 pg/mL and 78.4 pg/mL (median 19 ± 29 pg/mL); this change was significant according to a unilateral *t*-test of the decline of oestradiol levels (*P* = 0.033) ([Fig. 3](#fig3){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}). Pre-treatment serum alkaline phosphatase levels of 557 U/L dropped to 434 U/L following treatment ([Table 3](#tbl3){ref-type="table"}, *P* = 0.019). There were no significant changes in the levels of luteinising hormone, follicle-stimulating hormone, insulin-like growth factor 1, testosterone or prolactin owing to treatment ([Table 3](#tbl3){ref-type="table"}, *P* \> 0.05).Figure 3Oestradiol levels before and after letrozole treatment. There was a significant decrease in oestradiol levels over the treatment period. \**P* = 0.033. Table 3Hormone levels of McCune--Albright patients before and after letrozole therapy.SubjectE~2~ (pg/mL) (pre)E~2~ (pg/mL) (on)AP (U/L) (pre)AP (U/L) (on)LH (IU/L) (pre)LH (IU/L) (on)FSH (IU/L) (pre)FSH (IU/L) (on)T (ng/mL) (pre)T (nmol/L) (on)IGF-1 (ng/mL) (pre)IGF-1 (ng/mL) (on)PRL (ng/mL) (pre)PRL (ng/mL) (on)11652.57217010.10.880.783.370.220.18664Null51.868.725572.540654200.11.34.20.060.0521417419.93.7432.5810887410.320.840.688.290.050.16166Null4.56Null41611130832100.0102.870.010.1314129318.923.4527.331861830.020.170.62.730017450910.58.85620.8Null4692610.59Null2.3NullNullNull440Null6.47Null72.5584253950.260.40.10.10.050.0510627022.83.58882.54242370.10.10.732.230.050.051731989.845.81912.32.55402670.050.690.520.20.070.213394571118.61070078.410037180.720.053.170.170.080.31(−)Null14.520.3[^3]

Vaginal bleeding and pubertal staging
-------------------------------------

Pre- and on-treatment vaginal bleeding frequency data were available for all ten subjects. Among the girls who experienced this condition before therapy, vaginal bleeding occurred at a median frequency of 5.9 episodes per year (range 0--12). This frequency declined significantly following letrozole treatment, with eight subjects experiencing no bleeding episodes and one experiencing a single bleeding episode per year.

Pubertal stages of breasts and pubic hair stabilised during the treatment period (I--IV and I--III, respectively, before therapy vs I--V and I--III, respectively, after initiating treatment).

Subjects were also monitored for CPP, which typically develops in children with treated or untreated PPP. None of the subjects had CPP at baseline; however, subjects 5, 7, 9 and 10 subsequently entered central puberty while on letrozole. The mean chronologic age and bone age upon entrance into central puberty were 8.75 ± 0.96 (range 6--8) years and 7.43 ± 1.82 (range 8--10) years, respectively. Subjects with central puberty were treated with GnRH analogue therapy.

Adverse effects during treatment
--------------------------------

Patient 6 complained of repeated nettle-rash during the first 3 months of treatment; this resolved spontaneously within 1 year. None of the other patients developed any specific adverse events.

Discussion
==========

PP is the most common endocrinopathy in individuals with MAS. PP affects girls more often than boys, with vaginal bleeding being the initial manifestation. Autonomic activation of ovarian tissue leads to ovarian follicular cysts and elevated oestrogen levels. This status is defined as PPP since the hypothalamic--pituitary--gonadal axis is inactive, although progression to CPP may occur during follow-up ([@bib15], [@bib16]). Despite therapeutic advances, the treatment of MAS-associated PP remains challenging. Early reports of the first-generation aromatase inhibitor testolactone showed no sustained beneficial effects on skeletal growth or maturation ([@bib8], [@bib17]). The second-generation agent fadrozole was also found to block oestrogen synthesis insufficiently in most girls with MAS-associated PPP and possibly impaired the adrenocortical stress response ([@bib18]). The most potent third-generation aromatase inhibitor, letrozole, had mixed results ([@bib19], [@bib20]). Feuillan *et al*. ([@bib21]) performed a preliminary 3-year study of letrozole and reported that letrozole could be used as an alternative therapy for girls with MAS based on a decreased rate of skeletal maturation. In our retrospective cohort study, letrozole treatment was found to have beneficial effects on vaginal bleeding, skeletal maturation, growth velocity and PAH in girls with MAS-associated PP. Compared with pre-treatment oestradiol levels, on-treatment levels were significantly reduced from 182 ± 264 pg/mL to 19 ± 29 pg/mL. These findings were consistent with those of a previous study by Estrada *et al*. ([@bib22]).

We found that letrozole is an effective treatment for MAS-associated PP and is well tolerated with no severe adverse events, no increase in uterine volumes and no additional cases of torsion during the treatment or follow-up period. Other therapies have also been previously described. Fulvestrant, which binds to and rapidly degrades the oestrogen receptor, was found to be moderately effective in decreasing vaginal bleeding and the rate of skeletal maturation in girls with PPP over a 1-year period without causing uterine alterations or other serious adverse events ([@bib23]). Our study indicates that letrozole may be an effective and relatively safe treatment for girls with PPP, offering an alternative therapy for those who fail to respond to oestrogen blockers such as tamoxifen.

Thyroid disorder is the second most common endocrinopathy in MAS ([@bib24]), although there is no agreement regarding the frequency or the peculiarities of thyroid abnormalities. Involvement of the thyroid gland is a common and sometimes overlooked feature of MAS. Although thyroid cancer has been described in two patients with MAS, the prevalence of malignancy does not appear to be high ([@bib25]). A retrospective polycentric study of 36 MAS patients over 20 years found that the prevalence of thyroid alterations was 31%; 7 of 11 patients with thyroid alterations had nodular goitres, with nodules \>1 cm ([@bib26]). In our study, four patients (40%) showed functional and/or morphological thyroid abnormalities, and two (20%) had clinical hyperthyroidism with treatment. A strict monitoring of thyroid function is recommended every 6 months ([@bib26]). FD is the most common feature of MAS ([@bib27]) and can involve the craniofacial bones ([@bib28]). Eight patients in our study had polyostotic FD, seven of whom had both limb and craniofacial bone involvement.

The diagnosis of MAS is primarily clinical and radiological; although bone histology and genetic analysis do confirm the diagnosis, these are seldom required to confirm it ([@bib29]). The relative prevalence of the café-au-lait spots in a previously described Korean cohort of 14 patients with MAS followed over 16 years was 64% ([@bib30]). Similarly, café-au-lait spots were found in six of our ten patients (60%). Such skin pigmentation results from an activating mutation of melanocyte G(s)alpha and appears to be linked to tyrosinase gene production via cyclic adenosine monophosphate signalling ([@bib31]).

The ultimate outcome of interest in the treatment of PP is adult height; this requires extended follow-up times and is therefore rarely reported, particularly in rare disorders such as MAS. Despite the small sample size, letrozole treatment resulted in a statistically significant decrease in the BA/CA ratio, growth *Z*-score and growth velocity, as well as an increase in PAH, leading to an increased adult height; these data further support the efficacy of this therapy.

There were several limitations to our study. MAS is rare, and a very limited number of patients have received letrozole therapy; thus, data from an untreated control group of subjects were not available, and each subject served as her own control. However, the inclusion of patient data spanning 18 years enabled studying a reasonable sample size and generated statistically significant results. Notably, the study was also limited by the inherent disadvantages of retrospective analyses. Growth outcomes in MAS are complex and may be affected by multiple confounders such as skeletal deformities and other endocrinopathies. The latter include hyperthyroidism and growth hormone excess, which may accelerate growth, as well as Cushing syndrome, which may decelerate growth. All inherent endocrinopathies were assessed in our patients and managed medically. Further studies with a greater number of patients who completed treatment and reached skeletal maturity are required to confirm the effect of letrozole on adult height.
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[^1]: +, positivity; −, negativity; B/PH, breast/pubic hair; FD, fibrous dysplasia; GHH, growth hormone hypersecretion; HT, hyperthyroidism; PH, prolactin hypersecretion; PP, precocious puberty; QD, every day; QOD, every other day; SD, skin dysplasia (café-au-lait skin pigments); VD, visual deficit.

[^2]: BA/CA, bone age-to-chronological age ratio; on, on treatment; PAH, predicted adult height; pre, pre-treatment.

[^3]: AP, serum alkaline phosphatase; E~2~, oestradiol; FSH, follicle-stimulating hormone; IGF-1, insulin-like growth factor 1; LH, luteinising hormone; on, on treatment; pre, pre-treatment; PRL, prolactin; T, testosterone.
